Immunovia (IMMNOV) Q3 2024 earnings summary

Executive summary

• Achieved key milestones in next-generation pancreatic cancer test development, completing discovery, model development, and analytical validation; clinical validation to finish by December 2024.

• Next-generation test demonstrated 85% sensitivity and 98% specificity, outperforming CA19-9 by 20 percentage points in sensitivity at equivalent specificity.

• Transitioning from R&D to commercial phase in 2025, with a planned U.S. launch in H2 2025 and focus on strategic partnerships.

• Strong operational and financial execution, including significant cost reductions, successful capital raise, and ongoing strategic partnership discussions.

• Net sales for Q3 2024 were SEK 235k, all from royalties, with no test sales recorded; net earnings were SEK -51.1m, impacted by exchange rate effects and a one-time provision.

Financial highlights

• Q3 2024 operating expenses were 31.5 MSEK, down 20% year-over-year, with headcount costs dropping 62%.

• Q3 cash burn totaled SEK 21.2 million, a 40% reduction from last year; cash balance at quarter-end was SEK 54.2 million.

• Rights issue raised SEK 52.4 million net with 91% subscription, exceeding expectations and extending the cash runway for at least 12 months.

• Equity at period end was SEK 38.6 million, with an equity/assets ratio of 61%.

• Earnings per share before and after dilution for Q3 2024 was SEK -0.73.

Outlook and guidance

• Clinical validation results for the next-generation test expected in December 2024.

• U.S. test launch planned for H2 2025, initially under a patient-pay model; payer reimbursement expected in 2026.

• Cash burn projected at 8–10 MSEK/month in Q4 2024 due to increased R&D activity.

• OpEx will shift from R&D to studies supporting reimbursement and commercialization in 2025.

• Additional clinical studies in high-risk populations planned for 2025 to support reimbursement and market adoption.